Key result
In vivo administration of selective substrate-based inhibitors of mammalian DDAH increased plasma ADMA levels, providing proof of concept for their physiological effects.
Population
In vivo model (specifics not provided in abstract)
Design
Preclinical
Authors
Loading...
Offers preclinical tool to study DDAH-NO axis; leaves open translation to human disease.
The development of the first selective, reversible DDAH inhibitors provides a novel tool to probe the physiological effects of DDAH inhibition and a potential therapeutic approach for diseases with excess NO production.
Rossiter et al. (2005) studied this question. Substrate-based inhibitors of mammalian DDAH was evaluated on Plasma ADMA levels. In vivo administration of selective substrate-based inhibitors of mammalian DDAH increased plasma ADMA levels, providing proof of concept for their physiological effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: